Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®) ) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trial

Haemophilia. 2015 Sep;21(5):e436-9. doi: 10.1111/hae.12737. Epub 2015 Jun 8.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Confidence Intervals
  • Factor VIII / adverse effects*
  • Factor VIII / therapeutic use*
  • Hemophilia A / complications
  • Hemophilia A / drug therapy*
  • Hemorrhage / drug therapy*
  • Hemorrhage / etiology
  • Hemorrhage / prevention & control*
  • Hemostatics / therapeutic use
  • Humans
  • Infant
  • Middle Aged
  • Time Factors
  • Treatment Outcome
  • Young Adult

Substances

  • Hemostatics
  • recombinant factor VIII N8
  • Factor VIII